Skip to content

Study · Not a test of the peptide alone · 1996

6 results

Combined treatment with thymosin-alpha1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase-II controlled trial.

Salvati F, Rasi G, Portalone L, Antilli A, Garaci E

Anticancer research1 Mar 1996Cited by 35 (Europe PMC)

PMID8687090 (opens in a new tab)PepBankPUB-08687090
Publisher pageAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In advanced non-small-cell lung cancer, response rate was 33% with chemo-immunotherapy and 10% with chemotherapy alone, a difference that was not significant.

    In plain wordsIn people with advanced lung cancer, response rate was 33% with thymosin alpha1 plus interferon after chemotherapy and 10% with chemotherapy alone; not significant.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeResponse rate
    Study

    n = 22

    Comparator
    Chemotherapy (ifosfamide) alone
    Outcome group
    Tumor growth · Cancer

    Measurements

    Response rate
    33%
    chemo-immunotherapy
    Response rate
    10%
    chemotherapy alone

    Source sentences

    Summary
    Chemo-immunotherapy induced an enhanced response rate compared with chemotherapy alone (33% and 10% respectively). Although these differences were not significant, the difference in time to progression was (p=0.0059).
    1 context sentence
    Summary · context
    22 patients with advanced non-small-cell lung cancer were randomized to receive chemotherapy (ifosfamide) or chemotherapy followed by thymosin alpha1 + low-dose IFNalpha.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In advanced non-small-cell lung cancer, time to progression differed significantly between chemo-immunotherapy and chemotherapy alone (p=0.0059); the direction is not stated.

    In plain wordsIn people with advanced lung cancer, time to progression differed significantly between thymosin alpha1 plus interferon after chemotherapy and chemotherapy alone.

    Peptide
    Thymosin alpha-1
    Outcome
    Direction not reportedTime to progression
    Study

    n = 22

    Comparator
    Chemotherapy (ifosfamide) alone
    Outcome group
    Tumor growth · Cancer

    Measurements

    p value for time to progression
    0.0059 p
    chemo-immunotherapy vs chemotherapy

    Source sentences

    Summary
    the difference in time to progression was (p=0.0059).
    1 context sentence
    Summary · context
    22 patients with advanced non-small-cell lung cancer were randomized to receive chemotherapy (ifosfamide) or chemotherapy followed by thymosin alpha1 + low-dose IFNalpha.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In advanced non-small-cell lung cancer, CD4+ counts were depressed after chemotherapy but showed no change in patients given chemo-immunotherapy.

    In plain wordsIn people with advanced lung cancer, CD4+ cell counts fell after chemotherapy alone but did not fall with thymosin alpha1 plus interferon.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeCD4+ cell count after two chemotherapy cycles
    Study

    n = 22

    Comparator
    Chemotherapy (ifosfamide) alone
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    CD4+, CD8+ and NK cell counts were significantly depressed after two cycles of chemotherapy, while no difference in cell count were seen in chemo-immunotherapy treated patients.
    1 context sentence
    Summary · context
    22 patients with advanced non-small-cell lung cancer were randomized to receive chemotherapy (ifosfamide) or chemotherapy followed by thymosin alpha1 + low-dose IFNalpha.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In advanced non-small-cell lung cancer, CD8+ counts were depressed after chemotherapy but showed no change in patients given chemo-immunotherapy.

    In plain wordsIn people with advanced lung cancer, CD8+ cell counts fell after chemotherapy alone but did not fall with thymosin alpha1 plus interferon.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeCD8+ cell count after two chemotherapy cycles
    Study

    n = 22

    Comparator
    Chemotherapy (ifosfamide) alone
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    CD4+, CD8+ and NK cell counts were significantly depressed after two cycles of chemotherapy, while no difference in cell count were seen in chemo-immunotherapy treated patients.
    1 context sentence
    Summary · context
    22 patients with advanced non-small-cell lung cancer were randomized to receive chemotherapy (ifosfamide) or chemotherapy followed by thymosin alpha1 + low-dose IFNalpha.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 05HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In advanced non-small-cell lung cancer, NK cell counts were depressed after chemotherapy but showed no change in patients given chemo-immunotherapy.

    In plain wordsIn people with advanced lung cancer, NK cell counts fell after chemotherapy alone but did not fall with thymosin alpha1 plus interferon.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeNK cell count after two chemotherapy cycles
    Study

    n = 22

    Comparator
    Chemotherapy (ifosfamide) alone
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    CD4+, CD8+ and NK cell counts were significantly depressed after two cycles of chemotherapy, while no difference in cell count were seen in chemo-immunotherapy treated patients.
    1 context sentence
    Summary · context
    22 patients with advanced non-small-cell lung cancer were randomized to receive chemotherapy (ifosfamide) or chemotherapy followed by thymosin alpha1 + low-dose IFNalpha.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  6. 06HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialSafety outcome

    In advanced non-small-cell lung cancer, no grade 3/4 hematologic toxicity was seen with chemo-immunotherapy compared with 50% with chemotherapy alone.

    In plain wordsIn people with advanced lung cancer, no serious blood toxicity was seen with thymosin alpha1 plus interferon after chemotherapy, compared with 50% with chemotherapy alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseGrade 3/4 hematologic toxicity
    Study

    n = 22

    Comparator
    Chemotherapy (ifosfamide) alone
    Outcome group
    Adverse events · Cancer

    Measurements

    Grade 3/4 hematologic toxicity
    50%
    chemotherapy alone

    Source sentences

    Summary
    Hematologic toxicity was reduced by the immunotherapy, with no grade 3/4 toxicity seen compared to 50% in patients treated with chemotherapy alone.
    1 context sentence
    Summary · context
    22 patients with advanced non-small-cell lung cancer were randomized to receive chemotherapy (ifosfamide) or chemotherapy followed by thymosin alpha1 + low-dose IFNalpha.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.